摘要
AIM： To evaluate anti-angiogenic effect of tenomodulin （TNMD） and ranibizumab on cell proliferation and capillary- like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor （VEGF） in vitro. METHODS： The effects of TNMD and ranibizumab on VEGF-induced proliferation of human umbilical vein endothelial cells （HUVECs） were evaluated by MTT assay, and the effects of TNMD and ranibizumab on capillary- like structures formed by HUVECs under the stimulation of VEGF were examined in culture. Capillary-like morphogenesis of HUVECs was quantitatively evaluated, and total lengths of tube-like structures per field were measured in a masked way. RESULTS： HUVECs with both ranibizumab and TNMD protein showed MTT reduction in VEGF-stimulated cell proliferation as expected, while MTT absorbance in the HUVECs with TNMD was significantly declined than that with ranibizumab （P〈O.01）. The capillary-like structures formed by HUVECs were markedly impaired by the presence of both TNMD and ranibizumab in the culture medium. The total length of the capillary-like structures per field was significantly shorter in the medium with TNMD than that of ranibizumab （P〈0.01）. The inhibitory effect of TNMD on tube formation in vitro angiogenesis was significantly stronger than that of ranibizumab. CONCLUSION： TNMD may have stronger inhibitory effect than ranibizumab on in vitro angiogenesis.
AIM： To evaluate anti-angiogenic effect of tenomodulin （TNMD） and ranibizumab on cell proliferation and capillary- like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor （VEGF） in vitro. METHODS： The effects of TNMD and ranibizumab on VEGF-induced proliferation of human umbilical vein endothelial cells （HUVECs） were evaluated by MTT assay, and the effects of TNMD and ranibizumab on capillary- like structures formed by HUVECs under the stimulation of VEGF were examined in culture. Capillary-like morphogenesis of HUVECs was quantitatively evaluated, and total lengths of tube-like structures per field were measured in a masked way. RESULTS： HUVECs with both ranibizumab and TNMD protein showed MTT reduction in VEGF-stimulated cell proliferation as expected, while MTT absorbance in the HUVECs with TNMD was significantly declined than that with ranibizumab （P〈O.01）. The capillary-like structures formed by HUVECs were markedly impaired by the presence of both TNMD and ranibizumab in the culture medium. The total length of the capillary-like structures per field was significantly shorter in the medium with TNMD than that of ranibizumab （P〈0.01）. The inhibitory effect of TNMD on tube formation in vitro angiogenesis was significantly stronger than that of ranibizumab. CONCLUSION： TNMD may have stronger inhibitory effect than ranibizumab on in vitro angiogenesis.
基金
Supported by the Cooperation Fund for Clinic and Scientific Research of Capital Medical University(No.13JL13)
